Visual China.
Blue Whale financial reporter Li Minghao.
On December 7, the A-share innovative drug concept stocks collectively fell, and in the afternoon, the new Novo of CSPC Pharmaceutical Group continued to fall, approaching **, the share price of the new novo was **20%, and then firmly sealed the fall limit. As of **, the turnover of New Nova reached 227.4 billion yuan, and the stock price closed at 3812 yuan shares, with a total market value of 446$2.9 billion.
On September 12, Xinnuo Vision announced that it plans to increase the cash capital of CSPC Pharmaceutical Group Jushi Biotech, realize the holding of Jushi Biotech, and cut into the innovative drug track. Since then, its share price has climbed all the way to the ** price of 13 on September 1141 yuan shares**, as of December 7, its stock price has accumulated **184%.
For the rare fall limit of Xinnuovi, there are rumors in the market today that the chairman of Hengrun Co., Ltd. was detained for insider trading, which triggered a rumor that "the ** manager of SPDB AXA Company was taken away". According to public information, SPDB AXA Dividend began to hold a heavy position in New Nova in the third quarter, and as of the end of September, SPDB AXA Dividend still held New Novi 339550,000 shares.
However, then the reporter of the Financial Associated Press verified with SPDB AXA and learned that all the company's ** managers were working normally, and the rumor was untrue.
The stock price of innovative drugs rose sharply.
Xinnovo is a holding subsidiary of CSPC Pharmaceutical Group, which was jointly funded by CSPC Pharmaceutical Holdings and CSPC Import and Export in April 2006, and in 2019, CSPC Pharmaceutical Group spun it off and went public. As of the end of September, CSPC Pharmaceutical Group held a total of 7417% of the shares, the largest shareholder.
Originally, Xinnuowei was not involved in the innovative drug business, and its main business was the research and development, production and sales of functional foods in the field of health, and the main products were functional raw materials and health food products, of which the functional raw materials were mainly caffeine, acarbose, and anhydrous glucose, and the health food was mainly Guoweikang vitamin C lozenges and B vitamin lozenges.
On September 12, Novo announced that the company plans to implement a cash capital increase of 187.1 billion yuan, of which 104.1 billion yuan is included in the registered capital, 83 billion yuan is included in the capital reserve. Through the cash capital increase, New Novo will acquire 51% of the equity of Jushi Biotechnology and realize the control of Jushi Biotech.
Jushi Biopharma is a new force under CSPC Pharmaceutical Group, an innovative biopharmaceutical company with independent research and development capabilities as the core driving force, focusing on the frontier fields of biopharmaceuticals such as antibody drugs, antibody drug conjugates (ADCs) and mRNA vaccines. **Areas include breast cancer, cervical cancer, stomach cancer, psoriasis, etc.
As of September 12, Jushi Biotech has more than 20 projects under development, of which 1 mRNA vaccine product has been approved for emergency use in China, and 8 products have been in clinical trials at different stages in China or are in the process of applying for marketing, including 2 products in the application and marketing stage, 3 products in clinical phase II and phase III, and 3 products in clinical phase I.
However, like most innovative drug companies, Jushi Biotech has not yet achieved profitability. In 2021, 2022 and the first seven months of 2023, the company's operating income will be 0 yuan and 21.2 billion yuan, 3470010,000 yuan, net profit was -29.2 billion yuan, -43.8 billion yuan, -33.5 billion yuan. As of the end of July 2023, the total assets of Jushi Biotech are 205.7 billion yuan, total liabilities 136.9 billion yuan, net assets of 6$8.9 billion.
After the announcement, Xinnuowei changed from a functional food company to an innovative drug company, and the stock price also entered an upward channel.
In order to give more prominence to the direction of innovative drugs, Xinnovo even changed its name to optimize the corporate brand image. On November 20, Xinnuowei issued an announcement that the company completed the registration and filing procedures for industrial and commercial changes, and the full Chinese name of the company will be changed from CSPC Pharmaceutical Group Xinnovo Pharmaceutical Co., Ltd. *** to CSPC Pharmaceutical Innovation Pharmaceutical Co., Ltd. ***, but the ** abbreviation has not yet been changed.
For a series of operations of Xinnovo to cut into the innovative drug track, some industry insiders pointed out that whether it is Xinnovo's capital increase in CSPC Pharmaceutical Group, or whether it is Xinnovo's change of name to CSPC Pharmaceutical Innovation, in the end, it is just an asset transfer game of CSPC Pharmaceutical Group's "left hand to right hand", and in essence, there is no breakthrough in the group's business.
The private placement of 56 million shares was lifted.
Since the launch of the stock price of New Novo, many investors in the stock bar have said that they have missed the stage of New Novo because they "dare not get on the bus".
The main reason why investors have such concerns is that 56 million restricted shares of Xinnovi have just been listed and circulated on September 11. It is worth mentioning that the release date of the restricted shares is the day before the release of the capital increase plan of Jushi Biotechnology by New Novo.
On October 12, 2022, Xinnuowei received the "Approval on Agreeing to the Registration of CSPC Pharmaceutical Group's Xinnuowei Pharmaceutical Co., Ltd. to Purchase Assets and Raise Matching Funds by Issuing Shares to CSPC Pharmaceutical Group Enbipu Pharmaceutical Co., Ltd." issued by the China Securities Regulatory Commission on October 8, 2022, agreeing to the company's registration application for issuing shares to raise matching funds of no more than 500 million yuan.
On March 8, Xinnuowei issued an announcement that 16 subscription objects, including Caitong**, UBS AG, Ruihua Investment, and Nord**, were determined to be allotted to the issuance object, and the number of shares raised for matching funds was about 31.48 million shares, and the issuance ** was 1588 yuan shares, the total amount of funds raised is 49999999848 yuan.
On April 7, the 2022 Annual General Meeting of Shareholders was held to distribute a cash dividend of RMB 1 per 10 shares to all shareholders50 yuan, and at the same time, 8 shares for every 10 shares of all shareholders will be transferred to the capital reserve. After the completion of the conversion, the number of shares previously increased to about 56.67 million shares, accounting for 4 of the company's total share capital8410%。
According to the price of the new Novi ** on December 7, 3812 yuan shares** calculation, this part of the private placement of shares compared with 15The issuance of $88 shares has been 140% and it is not known whether the shares have been sold.